There’s an interesting relationship between psoriasis and exercise: While the condition can make playing sports and working ...

Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...

The combination of medications also showed increased inflammatory immune activity compared with Taltz alone.

Psoriasis is an inflammatory condition that causes thick, scaly patches on the skin that are flaky and shed easily. Symptoms can worsen with skin injury - through scratching, rubbing, or chafing - in ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Johnson & Johnson recently reported new two-year Phase 3 ICONIC-TOTAL data showing its oral peptide ICOTYDE® (icotrokinra) ...

Combining Taltz and Zepbound improves psoriasis symptoms and metabolic biomarkers in patients with obesity.

A new study finds that AI systems and large language models achieve at best 25 percent accuracy in diagnosing psoriasis in ...

A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...

Hair follicle cells may drive psoriasis inflammation through an S100A1-dependent pathway, offering a potential therapeutic ...

I’ve had psoriasis since I was 5 years old. It started as a little patch on my left ankle—I remember thinking, What’s this ...